SZSE:301520 (China)
Â
Class A Shares
Â¥
45.93
(+0.37%)
May 24
Current and historical daily PE Ratio for Anhui Wanbang Pharmaceutical Technology Co Ltd (
) from 2023 to May 26 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Anhui Wanbang Pharmaceutical Technology stock (SZSE:301520) PE ratio as of May 26 2024 is 25.06.
More Details
Anhui Wanbang Pharmaceutical Technology Co Ltd (SZSE:301520) PE Ratio (TTM) Chart
Anhui Wanbang Pharmaceutical Technology Co Ltd (SZSE:301520) PE Ratio (TTM) Historical Data
View and export this data going back to 2023. Start your Free Trial
Total 158
- 1
- 2
| Anhui Wanbang Pharmaceutical Technology PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-26 | 25.1 | 2024-03-18 | 29.8 |
| 2024-05-24 | 25.1 | 2024-03-15 | 28.6 |
| 2024-05-23 | 25.0 | 2024-03-14 | 29.4 |
| 2024-05-22 | 24.7 | 2024-03-13 | 29.8 |
| 2024-05-21 | 24.3 | 2024-03-12 | 29.4 |
| 2024-05-20 | 24.5 | 2024-03-11 | 28.3 |
| 2024-05-17 | 24.5 | 2024-03-08 | 27.6 |
| 2024-05-16 | 24.3 | 2024-03-07 | 27.1 |
| 2024-05-15 | 24.4 | 2024-03-06 | 28.1 |
| 2024-05-14 | 25.1 | 2024-03-05 | 27.8 |
| 2024-05-13 | 26.1 | 2024-03-04 | 29.4 |
| 2024-05-10 | 25.6 | 2024-03-01 | 27.1 |
| 2024-05-09 | 26.3 | 2024-02-29 | 27.4 |
| 2024-05-08 | 26.2 | 2024-02-28 | 27.0 |
| 2024-05-07 | 26.2 | 2024-02-27 | 28.4 |
| 2024-05-06 | 26.4 | 2024-02-26 | 28.3 |
| 2024-04-30 | 25.0 | 2024-02-23 | 27.6 |
| 2024-04-29 | 24.8 | 2024-02-22 | 27.1 |
| 2024-04-26 | 24.3 | 2024-02-21 | 27.0 |
| 2024-04-25 | 24.0 | 2024-02-20 | 27.0 |
| 2024-04-24 | 23.6 | 2024-02-19 | 26.3 |
| 2024-04-23 | 23.1 | 2024-02-08 | 25.9 |
| 2024-04-22 | 22.8 | 2024-02-07 | 24.2 |
| 2024-04-19 | 23.2 | 2024-02-06 | 24.9 |
| 2024-04-18 | 23.3 | 2024-02-05 | 23.7 |
| 2024-04-17 | 23.3 | 2024-02-02 | 25.1 |
| 2024-04-16 | 22.5 | 2024-02-01 | 26.5 |
| 2024-04-15 | 24.6 | 2024-01-31 | 25.6 |
| 2024-04-12 | 25.4 | 2024-01-30 | 27.3 |
| 2024-04-11 | 25.5 | 2024-01-29 | 28.9 |
| 2024-04-10 | 25.7 | 2024-01-26 | 28.8 |
| 2024-04-09 | 26.6 | 2024-01-25 | 30.3 |
| 2024-04-08 | 26.1 | 2024-01-24 | 27.9 |
| 2024-04-03 | 27.0 | 2024-01-23 | 27.3 |
| 2024-04-02 | 27.2 | 2024-01-22 | 27.3 |
| 2024-04-01 | 27.6 | 2024-01-19 | 30.2 |
| 2024-03-29 | 27.3 | 2024-01-18 | 30.7 |
| 2024-03-28 | 27.2 | 2024-01-17 | 30.7 |
| 2024-03-27 | 26.3 | 2024-01-16 | 31.3 |
| 2024-03-26 | 26.8 | 2024-01-15 | 29.9 |
| 2024-03-25 | 27.5 | 2024-01-12 | 29.9 |
| 2024-03-22 | 27.6 | 2024-01-11 | 30.4 |
| 2024-03-21 | 28.6 | 2024-01-10 | 29.1 |
| 2024-03-20 | 29.3 | 2024-01-09 | 29.7 |
| 2024-03-19 | 29.0 | 2024-01-08 | 30.1 |
Anhui Wanbang Pharmaceutical Technology Co Ltd (SZSE:301520) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Anhui Wanbang Pharmaceutical Technology Co Ltd
ISIN : CNE1000068J8
Share Class Description:
SZSE:301520: Class A SharesCompare
Compare
Traded in other countries / regions
301520.China IPO Date
2023-09-25Description
Anhui Wanbang Pharmaceutical Technology Co Ltd is a one-stop CRO service platform that engages in the entire process from pharmaceutical development to clinical research of innovative drugs, improved new drugs and generic drugs. It aims to provide drug research and development and clinical trials for drug launch, including pharmaceutical research, clinical services, biological sample analysis and testing, SMO services and data statistics and analysis.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers